Peter Pang

Peter Pang focuses on capital markets, private equity and cross-border mergers and acquisitions.

Highlights from Mr. Pang’s experience include representing:

Capital Markets

• China Renaissance Holdings Limited in its US$350 million Hong Kong IPO;
• NIO Inc. in its US$1 billion U.S. IPO. This was named as one of the 2018 Overseas Deals of the Year by China Business Law Journal and as one of Asian-MENA Counsel magazine’s Deals of the Year for 2018;
• VCREDIT Holdings Limited in its US$163 million Hong Kong IPO;
• Yixin Group Limited in its US$870 million Hong Kong IPO;
• the underwriters in the US$101 million U.S. IPO of Four Seasons Education (Cayman) Inc.;
• YY Inc. in its US$463 million follow-on American depositary shares (ADS) offering in August 2017;
• Ctrip.com International, Ltd. in its US$2.6 billion concurrent follow-on ADS offering and private placements of convertible notes and ordinary shares in September 2016; US$213 million convertible notes investments in MakeMyTrip Limited in May 2017 and January 2016; and US$1 billion convertible notes investment by The Priceline Group Inc. and another investment firm in December 2015; and
• Bitauto Holdings Limited in its Euroclear/Clearstream-settled Regulation S private placement of US$150 million aggregate principal amount of convertible notes in August 2016. 

M&A and Private Equity

• Capital Group Private Markets in its investment with GL Capital for approximately 29 percent stake in JINXIN Medical Investment Group Limited in June 2018;
• NIO Inc. in its Series D preferred share financing in November 2017;
• Ctrip.com International, Ltd. in its £1.4 billion acquisition of United Kingdom-based Skyscanner Holdings Limited through cross-border tender offer in December 2016;
• National Silicon Industry Group in its €170 million takeover of Okmetic Oyj through a voluntary public tender offer in November 2016;
• Tencent Holdings Limited in its:
  • US$42 million investment in Series D-2 preferred share financing of Yuanfudao in April 2016; and 
  • US$69 million acquisition, as part of an investor group including Huayi Brothers and other investors, of a 51 percent interest in China Jiuhao Health Industry Corporation Limited in February 2016; and
• The Carlyle Group in its US$64 million investment for a 15.7 percent stake in Zhongmei Healthcare Group Limited in January 2016.